Brookstone Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.3M | Buy |
144,784
+41,122
| +40% | +$5.42M | 0.18% | 137 |
|
|
2026
Q1 | $14.4M | Sell |
103,662
-11,708
| -10% | -$1.64M | 0.17% | 152 |
|
|
2025
Q4 | $14.2M | Sell |
115,370
-5,279
| -4% | -$642K | 0.16% | 153 |
|
|
2025
Q3 | $13.4M | Sell |
120,649
-2,639
| -2% | -$300K | 0.16% | 153 |
|
|
2025
Q2 | $13.7M | Buy |
123,288
+3,848
| +3% | +$410K | 0.18% | 138 |
|
|
2025
Q1 | $13.4M | Sell |
119,440
-28,012
| -19% | -$2.89M | 0.19% | 129 |
|
|
2024
Q4 | $13.6M | Buy |
147,452
+600
| +0.4% | +$54K | 0.2% | 121 |
|
|
2024
Q3 | $12.3M | Buy |
146,852
+992
| +0.7% | +$75.7K | 0.18% | 130 |
|
|
2024
Q2 | $10.7M | Buy |
145,860
+18,602
| +15% | +$1.24M | 0.18% | 137 |
|
|
2024
Q1 | $9.32M | Buy |
127,258
+112,305
| +751% | +$8.64M | 0.17% | 151 |
|
|
2023
Q4 | $1.21M | Buy |
14,953
+406
| +3% | +$31.6K | 0.02% | 418 |
|
|
2023
Q3 | $1.14M | Buy |
14,547
+1,390
| +11% | +$107K | 0.03% | 405 |
|
|
2023
Q2 | $979K | Buy |
13,157
+625
| +5% | +$49.8K | 0.02% | 439 |
|
|
2023
Q1 | $1.05M | Sell |
12,532
-2,415
| -16% | -$200K | 0.02% | 446 |
|
|
2022
Q4 | $1.32M | Sell |
14,947
-154,213
| -91% | -$12.2M | 0.03% | 377 |
|
|
2022
Q3 | $11.1M | Buy |
169,160
+9,145
| +6% | +$577K | 0.26% | 97 |
|
|
2022
Q2 | $10.1M | Buy |
160,015
+55,379
| +53% | +$3.43M | 0.22% | 110 |
|
|
2022
Q1 | $6.48M | Buy |
104,636
+28,881
| +38% | +$1.85M | 0.13% | 157 |
|
|
2021
Q4 | $5.4M | Sell |
75,755
-439
| -0.6% | -$30.2K | 0.09% | 174 |
|
|
2021
Q3 | $5.15M | Buy |
76,194
+12,760
| +20% | +$896K | 0.09% | 174 |
|
|
2021
Q2 | $4.31M | Buy |
63,434
+12,518
| +25% | +$836K | 0.08% | 193 |
|
|
2021
Q1 | $3.29M | Sell |
50,916
-959
| -2% | -$61.8K | 0.13% | 145 |
|
|
2020
Q4 | $3.02M | Buy |
51,875
+6,875
| +15% | +$415K | 0.12% | 140 |
|
|
2020
Q3 | $2.84M | Buy |
45,000
+13,514
| +43% | +$937K | 0.13% | 115 |
|
|
2020
Q2 | $2.42M | Sell |
31,486
-7,651
| -20% | -$586K | 0.15% | 99 |
|
|
2020
Q1 | $2.93M | Buy |
+39,137
| New | +$2.7M | 0.17% | 82 |
|
|
2019
Q4 | – | Sell |
-18,048
| Closed | -$1.14M | – | 434 |
|
|
2019
Q3 | $1.14M | Sell |
18,048
-16,456
| -48% | -$1.08M | 0.06% | 172 |
|
|
2019
Q2 | $2.33M | Buy |
+34,504
| New | +$2.27M | 0.13% | 125 |
|
|
2018
Q4 | – | Sell |
-63,479
| Closed | -$4.9M | – | 344 |
|
|
2018
Q3 | $4.9M | Sell |
63,479
-6,727
| -10% | -$508K | 0.37% | 68 |
|
|
2018
Q2 | $4.97M | Sell |
70,206
-2,348
| -3% | -$166K | 0.43% | 66 |
|
|
2018
Q1 | $5.47M | Buy |
72,554
+1,826
| +3% | +$145K | 0.5% | 65 |
|
|
2017
Q4 | $5.07M | Buy |
+70,728
| New | +$5.37M | 0.46% | 90 |
|
|
2015
Q4 | – | Sell |
-827
| Closed | -$81K | – | 436 |
|
|
2015
Q3 | $81K | Sell |
827
-494
| -37% | -$54.9K | 0.01% | 309 |
|
|
2015
Q2 | $155K | Buy |
+1,321
| New | +$144K | 0.02% | 266 |
|
Other funds holding GILD
LMFP
CIM
ATO
CGH
Brookstone Capital Management's GILD Position: Q2 2026 in Review
Brookstone Capital Management increased its Gilead Sciences (GILD) stake by 40% in Q2 2026, buying an estimated $5.42M and bringing the position to 144,784 shares worth $18.3M. The position accounts for 0.18% of the portfolio, ranked #137.
Brookstone Capital Management first reported a position in GILD in Q2 2015 and has held it in 34 quarters since. 556 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Brookstone Capital Management held 144,784 shares of Gilead Sciences worth $18.3M as of Q2 2026.
- Brookstone Capital Management bought 41,122 Gilead Sciences shares in Q2 2026, an estimated $5.42M.
- Gilead Sciences made up 0.18% of Brookstone Capital Management's portfolio in Q2 2026, its #137 holding.
- Brookstone Capital Management first reported a position in Gilead Sciences in Q2 2015 and has held it in 34 quarters since.
- 556 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Brookstone Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.